Latus Bio Inc. has launched with a focus on developing novel gene therapy candidates for central nervous system (CNS) disorders. An initial close of $54 million in series A financing will support the company.

Cerevance Inc. has announced the achievement of the first milestone in its research collaboration with Merck & Co.

Pain treatment, especially non-addictive treatment for severe pain, remains a critical unmet need. Among the TRP channels, transient receptor potential cation channel subfamily M member 3 (TRMP3) is a channel expressed in somatosensory neurons, including nociceptors of rodents and humans.

Researchers from Biohaven Pharmaceuticals Inc. presented preclinical data for the first-in-class extracellular bispecific IgG degrader, BHV-1300, being developed for the treatment of neuroinflammatory and autoimmune disease.

Proof-of-concept findings had shown that mRNA silencing of striatal Cav1.3 channels prevented and reversed established levodopa-induced dyskinesia in parkinsonian rats, with these effects being maintained in aged rats.

The U.S. FDA has cleared Centessa Pharmaceuticals plc’s IND to initiate a phase I first-in-human, clinical trial of ORX-750 for the treatment of narcolepsy.

The generation of pathogenic autoantibodies is a crucial event in the development of inflammation and complement activation, leading to immune cell responses.

Ipsen SA and Skyhawk Therapeutics Inc. have entered an exclusive worldwide collaboration to discover and develop small molecules that modulate RNA for rare neurological diseases. Skyhawk has a unique platform that accelerates building RNA-targeting small molecules across several therapeutic areas.